|
1
|
Dillion CF, Hirsch R, Rasch EK and Gu Q:
Symptomatic hand osteoarthritis in the United States: prevalence
and functional impairment estimates from the third U.S. National
Health and Nutrition Examination Survey 1991–1994. Am J Phys Med
Rehabil. 86:12–21. 2007.PubMed/NCBI
|
|
2
|
Fautrel B, Hilliquin P, Rozenberg S, et
al: Impact of osteoarthritis: results of nationwide survey of
10,000 patients consulting for OA. Joint Bone Spine. 72:235–240.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rabenda V, Manette C, Lemmens R, et al:
Direct and indirect costs attributable to osteoarthritis in active
subjects. J Rheumatol. 33:1152–1158. 2006.PubMed/NCBI
|
|
4
|
Gabriel SE, Crowson CS, Campion ME and
O'Fallon WM: Direct medical costs unique to people with arthritis.
J Rheumatol. 24:719–725. 1997.PubMed/NCBI
|
|
5
|
Gupta S, Hawker GA, Laporte A, Croxford R
and Coyte PC: The economic burden of disabling hip and knee
osteoarthritis (OA) from the perspective of individuals living with
this condition. Rheumatology (Oxford). 44:1531–1537. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le Pen C, Reygrobellet C and Gérentes I:
Financial costs of osteoarthritis in France. The ‘COART’ France
study Joint Bone. Spine. 72:567–570. 2005.
|
|
7
|
Zhang W, Moskowitz RW, Nuki G, et al:
OARSI recommendations for the management of hip and knee
osteoarthritis, Part I: critical appraisal of existing treatment
guidelines and systematic review of current research evidence.
Osteoarthritis Cartilage. 15:981–1000. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang W, Moskowitz RW, Nuki G, et al:
OARSI recommendations for the management of hip and knee
osteoarthritis, Part II: OARSI evidence-based, expert consensus
guidelines. Osteoarthritis Cartilage. 16:137–162. 2008. View Article : Google Scholar
|
|
9
|
Zhang W, Doherty M, Arden N, et al: EULAR
evidence-based recommendations for the management of hip
osteoarthritis: report of a task force of the EULAR Standing
Committee for International Clinical Studies Including Therapeutics
(ESCISIT). Ann Rheum Dis. 64:669–681. 2005. View Article : Google Scholar
|
|
10
|
Zhang W, Doherty M, Leeb BF, et al: EULAR
evidence-based recommendations for the management of hand
osteoarthritis: report of a task force of the EULAR Standing
Committee for International Clinical Studies Including Therapeutics
(ESCISIT). Ann Rheum Dis. 66:377–388. 2007. View Article : Google Scholar
|
|
11
|
Jordan KM, Arden NK, Doherty M, et al:
EULAR Recommendations 2003: an evidence-based approach to the
management of knee osteoarthritis: report of a task force of the
Standing Committee for International Clinical Studies Including
Therapeutics (ESCISIT). Ann Rheum Dis. 62:1145–1155. 2003.
View Article : Google Scholar
|
|
12
|
Pincus T, Koch GG, Sokka T, et al: A
randomized, double-blind, crossover clinical trial of diclofenac
plus misoprostol versus acetaminophen in patients with
osteoarthritis of the hip or knee. Arthritis Rheum. 44:1587–1598.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Case JP, Baliunas AJ and Block JA: Lack of
efficacy of acetaminophen in treating symptomatic knee
osteoarthritis: a randomized, double-blind, placebo-controlled
comparison trial with diclofenac sodium. Arch Intern Med.
163:169–178. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta I, Gupta V, Parihar A, et al:
Effects of Boswellia serrata gum resin in patients with bronchial
asthma: results of a double-blind, placebo-controlled, 6-week
clinical study. Eur J Med Res. 3:511–514. 1998.PubMed/NCBI
|
|
15
|
Sander O, Herborn G and Rau R: Is H15
(resin extract of Boswellia serrata, ‘incense’) a useful supplement
to establish drug therapy of chronic polyarthritis? Results of a
double-blind pilot study. Z Rheumatol. 57:11–16. 1998.(In
German).
|
|
16
|
Gerhardt H, Seifert F, Buvari P, et al:
Therapy of active Crohn disease with Boswellia serrata extract H15.
Z Gastroenterol. 39:11–17. 2001.(In German).
|
|
17
|
Kimmatkar N, Thawani V, Hingorani L and
Khiyani R: Efficacy and tolerability of Boswellia serrata extract
in treatment of osteoarthritis of knee - a randomized,
double-blind, placebo-controlled trial. Phytomedicine. 10:3–7.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sontakke S, Thawani V, Pimpalkhute P, et
al: Open, randomized, controlled clinical trial of Boswellia
serrata extract as compared to valdecoxib in osteoarthritis of the
knee. Indian J Pharmacol. 39:27–29. 2007. View Article : Google Scholar
|
|
19
|
Sengupta K, Alluri KV, Satish AR, et al: A
double-blind, randomized, placebo-controlled study of the efficacy
and safety of 5-Loxin for treatment of osteoarthritis of the knee.
Arthritis Res Ther. 10:R852008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Madisch A, Miehlke S, Eichele O, et al:
Boswellia serrata extract for the treatment of collagenous colitis.
A double-blind, randomized, placebo-controlled, multicenter trial.
Int J Colorectal Dis. 22:1445–1451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Safayhi H, Mack T, Sabieraj J, Anazodo MI,
Subramanian LR and Ammon HP: Boswellic acids: novel, specific,
nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther.
261:1143–1146. 1992.PubMed/NCBI
|
|
22
|
Sailer ER, Subramanian LR, Rall B,
Hoernlein RF, Ammon HP and Safayhi H: Acetyl-11-keto-beta-boswellic
acid (AKBA): structure requirements for binding and 5-lipoxygenase
inhibitory activity. Br J Pharmacol. 117:615–618. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sailer ER, Schweizer S, Boden SE, Ammon HP
and Safayhi H: Characterization of an acetyl-11-keto-beta-boswellic
acid and arachidonate-binding regulatory site of 5-lipoxygenase
using photoaffinity labeling. Eur J Biochem. 256:364–368. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu JJ, Nilsson A, Oredsson S, Badmaev V,
Zhao WZ and Duan RD: Boswellic acids trigger apoptosis via a
pathway dependent on caspase-8 activation but independent on
Fas/Fas ligand interaction in colon cancer HT-29 cells.
Carcinogenesis. 23:2087–2093. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shoba G, Joy D, Joseph T, Majeed M,
Rajendran R and Srinivas PS: Influence of piperine in
pharmacokinetics of curcumin in animals and human volunteers.
Planta Med. 64:353–356. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schweizer S, von Brocke AF, Boden SE,
Bayer E, Ammon HP and Safayhi H: Workup-dependent formation of
5-lipoxygenase-inhibitory boswellic acid analogues. J Nat Prod.
63:1058–1061. 2000. View Article : Google Scholar : PubMed/NCBI
|
